Phase 2 Neoadjuvant Study of Enzalutamide and Paclitaxel in the Treatment of LAR-Enriched TNBC: Trial Results and Insight Into ARness-Reference-Cited by-同舟云学术

Phase 2 Neoadjuvant Study of Enzalutamide and Paclitaxel in the Treatment of LAR-Enriched TNBC: Trial Results and Insight Into ARness

Published:2023 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Lim Bora,Seth Sahil,Yam Clinton,Huo Lei,Fujii Takeo,Lee Jangsoon,Bassett Jr Roland L.,Nasser Sara,Ravenberg Lisa,White Jason,Clayborn Alyson,Guerra Gil,Litton Jennifer K.,Damodaran Senthil,Layman Rachel M.,Valero Vicente,Tripathy Debasish,Lewis Michael T.,Dobrolecki Lacey,Lei Jonathan,Candelaria Rosalind,Arun Banu,Rauch Gaiane M.,Zhao Li,Zhang Jianhua,Ding Qingqing,Symmans W. Fraser,Thompson Alastair,Moulder Stacy,Ueno Naoto T.

Publisher

Elsevier BV

Reference142 articles.

1. Pembrolizumab for Early Triple-Negative Breast Cancer;P Schmid;The New England journal of medicine,2020

2. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer;C Liedtke;Journal of clinical oncology : official journal of the American Society of Clinical Oncology,2008

3. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial;H Bonnefoi;Ann Oncol,2014

4. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer;S Chen;Annals of surgical oncology,2015

5. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype;W F Symmans;J Clin Oncol,2017